Improving the Benefit/Risk Ratio
Using the smallest effective dose of warfarin, clearly will diminish hemorrhage. But there are more than a dozen factors other than dose that can either favorably effect the benefit/risk ratio or tell the physician that he should or should not consider using warfarin in specific patient groups. Three of these factors, the prothrombin time, warfarin resistance, and drug-drug interactions, have already been commented upon at this symposium and so I shall discuss several other factors.
KeywordsOral Anticoagulant Cerebral Hemorrhage Warfarin Therapy Prosthetic Heart Valve Anticoagulant Prophylaxis
Unable to display preview. Download preview PDF.
- 1.S. Wessler, A Guide to Anticoagulant Therapy, American Heart Association, 1984.Google Scholar
- 2.S. Wessler, Is anticoagulant prophylaxis of cardiac emboli practical?, Geriatrics (in press).Google Scholar
- 4.R. A. O’Reilly, and P. M. Aggeler, Determination of the response to oral anticoagulant drugs in man. Pharmacol Rev 22:35, 1980.Google Scholar
- 5.K. Fries, F. E. Konig, and T. Reich, Einfluss der Marcoumar-Therapie bei voll gestillten kindern, Schweiz Med Wochen Schr, 87:615(1957).Google Scholar
- 7.S. Wessler, S. N. Gitel, H. Bank, U. Martinowitz, and R. C. Stephenson, An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits, Thromb Haemost 40:486(1978).Google Scholar